Related Experiment Video
Updated: Jun 10, 2025
07:30
Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
10.0K
Shadows and lights in sepsis immunotherapy.
Guillaume Monneret1,2, Muzhda Haem Rahimi1,2, Anne-Claire Lukaszewicz2,3
1Hospices Civils de Lyon, Immunology Laboratory, Hôpital E. Herriot, Lyon, France.
Expert Opinion on Pharmacotherapy
|October 17, 2024
Summary
Sepsis treatment is shifting to precision medicine. Biomarkers will help personalize immunotherapy, improving patient outcomes by tailoring treatments to individual immuno-inflammatory responses.
Area of Science:
- Immunology and critical care medicine.
- Translational research in sepsis management.
Background:
- Sepsis presents a significant global health burden.
- The host response involves complex inflammatory and immunosuppressive mechanisms.
- Previous "one size fits all" anti-inflammatory therapies have shown limited success.
Purpose of the Study:
- To highlight the evolution of sepsis management towards precision medicine.
- To emphasize the importance of patient stratification using biomarkers.
- To discuss the role of multi-omics in defining immuno-inflammatory trajectories.
Main Methods:
- Review of current understanding of sepsis pathophysiology.
- Discussion of emerging precision medicine strategies.
- Exploration of biomarker utility in clinical practice and research.
Main Results:
- Precision medicine offers a personalized approach to immunotherapy (anti-inflammatory or immunostimulatory).
- Biomarker-based patient stratification is crucial for upcoming clinical trials.
- Standardized use of transcriptomics and multi-omics is expected to enhance biomarker discovery.
Conclusions:
- Personalized immunotherapy holds promise for improving sepsis outcomes.
- Biomarker-driven stratification is key to advancing sepsis treatment.
- Integration of multi-omics technologies will refine patient management strategies.
